GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Research & Development

Astellas Pharma (TSE:4503) Research & Development : 円327,651 Mil (TTM As of Mar. 2025)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Astellas Pharma's Research & Development for the three months ended in Mar. 2025 was 円76,229 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was 円327,651 Mil.

Astellas Pharma Research & Development Historical Data

The historical data trend for Astellas Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Research & Development Chart

Astellas Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 224,489.00 246,010.00 276,128.00 294,187.00 327,651.00

Astellas Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77,853.00 86,821.00 85,509.00 79,092.00 76,229.00

Astellas Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円327,651 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma  (TSE:4503) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Astellas Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Research & Development
Comparable Companies
TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY
Traded in Other Exchanges
ALPMY:USA ALPMF:USA YPH:Germany
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Website
http://www.astellas.com
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines